

Mednet, Biovisiq deal helps in zero-delay of trials

03 April 2013 | News | By BioSpectrum Bureau

AG Mednet, Biovisiq deal to reduce image-related query stoppages in trials



Singapore: AG Mednet signed a master services agreement with Biovisiq, a Japanese imaging core laboratory (ICL), to reduce image-related query stoppages in clinical trials, which can delay a trial for up to seven weeks. The aim of the agreement is to make zero-delay imaging technology a new industry standard for imaging data quality, compliance and efficiency.

The AG Mednet Submission Quality and Compliance module immediately detects errors that result in query stoppages and gives ICLs a system to verify information, automatically update support systems including electronic data capture (EDC), and dramatically reduce the amount of queries returned for correction or re-scanning.

In clinical trials conducted using AG Mednet technology, sponsors experience a more than 75 percent query reduction rate, resulting in significant cost savings and faster decision times.

Mr Shigeto Ogawa, president and CEO, Biovisiq, said that, "Biovisiq is dedicated to providing reliable, cost-effective and compliant imaging services to Japan and the growing Asian pharmaceutical market. We are confident that our partnership with AG Mednet will help accomplish this goal."

Mr Abraham Gutman, president and CEO, AG Mednet, said that, "Asia is the next frontier in clinical trial research as recruitment in the United States and Western Europe is getting harder to achieve. As clinical trials move closer to the patient base across Asia, we look forward to working with the talented team at Biovisiq to make a significant contribution to the Asia and Japan-specific drug discovery and development markets."